The peptide completed six randomized, double-blind, placebo-controlled clinical trials involving over 900 participants, establishing excellent safety and tolerability
Where appropriate vitamin B12 will be supplied, but because of the current situation it may be that the interval needs to be extended, bearing in mind that the virus is spreading so quickly and front-line medical staff have to be protected
It is administered as an injection under medical supervision and should not be self-injected unless trained by a healthcare professional
This page outlines the once-daily subcutaneous approach and is presented for research and educational purposes
Protects High-Risk Individuals People with hypertension, kidney illness, or anxiety disorders should be cautiously dosed to avoid symptom flare-ups like chest tightness, increased heart rate, swelling, or nervousness
Regulatory and safety status: TA-1 is pending FDA review and not currently approved for use in humans